NRSN

Neurosense Therapeutics Ltd

• TipRanks·04/28 19:57

  NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price

• PUBT·04/28 18:30

  NeuroSense prices $600,000 private placement at $0.8 per share

• PR Newswire·04/28 18:30

  NeuroSense Announces Pricing of Insider-Led PIPE Financing

• TipRanks·04/27 14:40

  Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Eton Pharmaceuticals (ETON) and Ligand Pharma (LGND)

• TipRanks·04/26 22:31

  NeuroSense announces departure of Chief Medical Officer

• TipRanks·04/24 13:47

  NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones

• PUBT·04/24 13:20

  NeuroSense CMO Ferenc Tracik steps down, effective April 27

• Dow Jones·04/08 12:13

  NeuroSense Therapeutics Is Maintained at Buy by D. Boral Capital

• Dow Jones·04/08 12:13

  NeuroSense Therapeutics Price Target Maintained With a $14.00/Share by D. Boral Capital

• TipRanks·04/07 13:40

  Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Opus Genetics (IRD)

• TipRanks·04/06 13:56

  NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC

• Benzinga·04/06 13:21

  NeuroSense Therapeutics Granted Patent From Brazilian Patent And Trademark Office Entitled 'Compositions Comprising Ciprofloxacin And Celecoxib'

• Reuters·04/06 13:20

  NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042

• PR Newswire·04/06 13:20

  NeuroSense Granted Brazilian Patent Covering PrimeC Composition

• Benzinga·04/06 07:19

  Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026